Cargando…

A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA

BACKGROUND: Curene® is a bioavailable formulation of turmeric  Curcucma longa extract comprising naturally derived curcuminoids formulated with proprietary Aquasome® technology. Curcuminoids were found to have anti-inflammatory properties by inhibiting Cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-...

Descripción completa

Detalles Bibliográficos
Autores principales: Panda, Sanjib kumar, Nirvanashetty, Somashekara, Parachur, Vivek A., Mohanty, Nilima, Swain, Tathastu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222223/
https://www.ncbi.nlm.nih.gov/pubmed/30498758
http://dx.doi.org/10.1155/2018/5291945
_version_ 1783369158296076288
author Panda, Sanjib kumar
Nirvanashetty, Somashekara
Parachur, Vivek A.
Mohanty, Nilima
Swain, Tathastu
author_facet Panda, Sanjib kumar
Nirvanashetty, Somashekara
Parachur, Vivek A.
Mohanty, Nilima
Swain, Tathastu
author_sort Panda, Sanjib kumar
collection PubMed
description BACKGROUND: Curene® is a bioavailable formulation of turmeric  Curcucma longa extract comprising naturally derived curcuminoids formulated with proprietary Aquasome® technology. Curcuminoids were found to have anti-inflammatory properties by inhibiting Cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) enzyme and hence have potential application in the treatment of Osteoarthritis (OA). To evaluate the safety and efficacy of Curene® a randomized, double blind, placebo controlled, parallel-group study was conducted in subjects with knee OA. Significant improvements in clinical endpoints were observed during the trial along with excellent safety profile. METHODS: Fifty (50) subjects aged between 40 and 75 years who were suffering from unilateral or bilateral OA of the knee for greater than 3 months according to American College of Rheumatology (ACR) criteria were enrolled. They were randomized into two treatment groups; one group received Curene® 500 mg once daily and the other group received placebo. Efficacy was evaluated using change from baseline in Visual Analogue Scale (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score. Biochemical and hematological parameters including urine analysis were performed to evaluate the safety of Curene® in OA patients. RESULT: Forty-six (46) subjects completed the study. The reduction from baseline in total WOMAC score (also subscale scores) and VAS score resulted in statistically significant difference when compared to placebo. It was also found to be safe and well tolerated as there was no incidence of treatment related AEs. CONCLUSION: Curene® results in statistically significant and clinically meaningful reduction in pain, stiffness, and improvement in physical functioning in subjects suffering from knee OA. Curene® also demonstrates excellent safety profile during the study. TRIAL REGISTRATION: This trial is registered with Clinical Trial Registry, India, CTRI/2017/07/009044, registered on 14th July 2017, http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=19264&EncHid=&userName=ocius%20life%20sciences.
format Online
Article
Text
id pubmed-6222223
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-62222232018-11-29 A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA Panda, Sanjib kumar Nirvanashetty, Somashekara Parachur, Vivek A. Mohanty, Nilima Swain, Tathastu Biomed Res Int Clinical Study BACKGROUND: Curene® is a bioavailable formulation of turmeric  Curcucma longa extract comprising naturally derived curcuminoids formulated with proprietary Aquasome® technology. Curcuminoids were found to have anti-inflammatory properties by inhibiting Cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) enzyme and hence have potential application in the treatment of Osteoarthritis (OA). To evaluate the safety and efficacy of Curene® a randomized, double blind, placebo controlled, parallel-group study was conducted in subjects with knee OA. Significant improvements in clinical endpoints were observed during the trial along with excellent safety profile. METHODS: Fifty (50) subjects aged between 40 and 75 years who were suffering from unilateral or bilateral OA of the knee for greater than 3 months according to American College of Rheumatology (ACR) criteria were enrolled. They were randomized into two treatment groups; one group received Curene® 500 mg once daily and the other group received placebo. Efficacy was evaluated using change from baseline in Visual Analogue Scale (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score. Biochemical and hematological parameters including urine analysis were performed to evaluate the safety of Curene® in OA patients. RESULT: Forty-six (46) subjects completed the study. The reduction from baseline in total WOMAC score (also subscale scores) and VAS score resulted in statistically significant difference when compared to placebo. It was also found to be safe and well tolerated as there was no incidence of treatment related AEs. CONCLUSION: Curene® results in statistically significant and clinically meaningful reduction in pain, stiffness, and improvement in physical functioning in subjects suffering from knee OA. Curene® also demonstrates excellent safety profile during the study. TRIAL REGISTRATION: This trial is registered with Clinical Trial Registry, India, CTRI/2017/07/009044, registered on 14th July 2017, http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=19264&EncHid=&userName=ocius%20life%20sciences. Hindawi 2018-10-25 /pmc/articles/PMC6222223/ /pubmed/30498758 http://dx.doi.org/10.1155/2018/5291945 Text en Copyright © 2018 Sanjib kumar Panda et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Panda, Sanjib kumar
Nirvanashetty, Somashekara
Parachur, Vivek A.
Mohanty, Nilima
Swain, Tathastu
A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA
title A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA
title_full A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA
title_fullStr A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA
title_full_unstemmed A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA
title_short A Randomized, Double Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Curene® versus Placebo in Reducing Symptoms of Knee OA
title_sort randomized, double blind, placebo controlled, parallel-group study to evaluate the safety and efficacy of curene® versus placebo in reducing symptoms of knee oa
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222223/
https://www.ncbi.nlm.nih.gov/pubmed/30498758
http://dx.doi.org/10.1155/2018/5291945
work_keys_str_mv AT pandasanjibkumar arandomizeddoubleblindplacebocontrolledparallelgroupstudytoevaluatethesafetyandefficacyofcureneversusplaceboinreducingsymptomsofkneeoa
AT nirvanashettysomashekara arandomizeddoubleblindplacebocontrolledparallelgroupstudytoevaluatethesafetyandefficacyofcureneversusplaceboinreducingsymptomsofkneeoa
AT parachurviveka arandomizeddoubleblindplacebocontrolledparallelgroupstudytoevaluatethesafetyandefficacyofcureneversusplaceboinreducingsymptomsofkneeoa
AT mohantynilima arandomizeddoubleblindplacebocontrolledparallelgroupstudytoevaluatethesafetyandefficacyofcureneversusplaceboinreducingsymptomsofkneeoa
AT swaintathastu arandomizeddoubleblindplacebocontrolledparallelgroupstudytoevaluatethesafetyandefficacyofcureneversusplaceboinreducingsymptomsofkneeoa
AT pandasanjibkumar randomizeddoubleblindplacebocontrolledparallelgroupstudytoevaluatethesafetyandefficacyofcureneversusplaceboinreducingsymptomsofkneeoa
AT nirvanashettysomashekara randomizeddoubleblindplacebocontrolledparallelgroupstudytoevaluatethesafetyandefficacyofcureneversusplaceboinreducingsymptomsofkneeoa
AT parachurviveka randomizeddoubleblindplacebocontrolledparallelgroupstudytoevaluatethesafetyandefficacyofcureneversusplaceboinreducingsymptomsofkneeoa
AT mohantynilima randomizeddoubleblindplacebocontrolledparallelgroupstudytoevaluatethesafetyandefficacyofcureneversusplaceboinreducingsymptomsofkneeoa
AT swaintathastu randomizeddoubleblindplacebocontrolledparallelgroupstudytoevaluatethesafetyandefficacyofcureneversusplaceboinreducingsymptomsofkneeoa